379 related articles for article (PubMed ID: 22183743)
1. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
Park SS; Daftari I; Phillips T; Morse LS
Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
[TBL] [Abstract][Full Text] [Related]
2. 24-Gy low-voltage x-ray irradiation with ranibizumab therapy for neovascular AMD: 6-month safety and functional outcomes.
Canton VM; Quiroz-Mercado H; Velez-Montoya R; Lopez-Miranda MJ; Moshfeghi AA; Shusterman EM; Kaiser PK; Sanislo SR; Gertner M; Moshfeghi DM
Ophthalmic Surg Lasers Imaging; 2012; 43(1):20-4. PubMed ID: 22251841
[TBL] [Abstract][Full Text] [Related]
3. 16 and 24 Gy low-voltage X-ray irradiation with ranibizumab therapy for neovascular age-related macular degeneration: 12-month outcomes.
Morales-Canton V; Quiroz-Mercado H; Velez-Montoya R; Zavala-Ayala A; Moshfeghi AA; Shusterman EM; Kaiser PK; Sanislo SR; Gertner M; Moshfeghi DM
Am J Ophthalmol; 2013 Jun; 155(6):1000-1008.e2. PubMed ID: 23497847
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
[TBL] [Abstract][Full Text] [Related]
5. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
[TBL] [Abstract][Full Text] [Related]
6. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.
Cho HJ; Kim CG; Yoo SJ; Cho SW; Lee DW; Kim JW; Lee JH
Am J Ophthalmol; 2013 Jan; 155(1):118-126.e1. PubMed ID: 23022163
[TBL] [Abstract][Full Text] [Related]
7. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
[TBL] [Abstract][Full Text] [Related]
8. Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings.
Cohen SY; Oubraham H; Uzzan J; Dubois L; Tadayoni R
Retina; 2012 Sep; 32(8):1480-5. PubMed ID: 22258164
[TBL] [Abstract][Full Text] [Related]
9. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
[TBL] [Abstract][Full Text] [Related]
10. Multifocal pupillography identifies ranibizumab-induced changes in retinal function for exudative age-related macular degeneration.
Sabeti F; Maddess T; Essex RW; James AC
Invest Ophthalmol Vis Sci; 2012 Jan; 53(1):253-60. PubMed ID: 22159011
[TBL] [Abstract][Full Text] [Related]
11. The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration.
Zweifel SA; Saroj N; Shapiro H; Freund KB
Retina; 2012 Jul; 32(7):1243-9. PubMed ID: 22466461
[TBL] [Abstract][Full Text] [Related]
12. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
[TBL] [Abstract][Full Text] [Related]
13. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration.
Gomi F; Sawa M; Tsujikawa M; Nishida K
Retina; 2012 Oct; 32(9):1804-10. PubMed ID: 22718152
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study.
Flaxel C; Schain MB; Hamon SC; Francis PJ
Retina; 2012 Mar; 32(3):417-23. PubMed ID: 21862953
[TBL] [Abstract][Full Text] [Related]
15. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration.
Rauch R; Weingessel B; Maca SM; Vecsei-Marlovits PV
Retina; 2012 Jul; 32(7):1260-4. PubMed ID: 22186738
[TBL] [Abstract][Full Text] [Related]
16. Ranibizumab for the treatment of exudative age-related macular degeneration associated with retinal pigment epithelial tear.
Rouvas AA; Ladas ID; Georgalas I; Vergados I; Papakonstantinou D; Kotsolis AI
Retina; 2011 Jun; 31(6):1083-8. PubMed ID: 21427630
[TBL] [Abstract][Full Text] [Related]
17. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results.
Dugel PU; Petrarca R; Bennett M; Barak A; Weinberger D; Nau J; Jackson TL
Ophthalmology; 2012 Jul; 119(7):1425-31. PubMed ID: 22465819
[TBL] [Abstract][Full Text] [Related]
18. Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy.
Inoue M; Arakawa A; Yamane S; Kadonosono K
Retina; 2013 May; 33(5):990-7. PubMed ID: 23446653
[TBL] [Abstract][Full Text] [Related]
19. Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration.
Lala C; Framme C; Wolf-Schnurrbusch UE; Wolf S
Acta Ophthalmol; 2013 Sep; 91(6):526-30. PubMed ID: 22697404
[TBL] [Abstract][Full Text] [Related]
20. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]